全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 68767-14-6 |
|---|---|---|---|
| 分子式 | 68767-14-6 | 纯度 | 98% |
| 分子量 | 246.3 | 货号 | abs47027081 |
| 规格 | 10mg | 供货周期 | 现货 |
| 主要用途 | is a non-steroidal anti-inflammatory dr | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Loxoprofen 68767-14-6
| 产品描述 | |
| 描述 | Loxoprofen is a non-steroidal anti-inflammatory drug. |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 洛索洛芬 |
| 外观 | 白色至淡黄色结晶粉末 |
| 可溶性/溶解性 | DMSO : 46 mg/mL (186.8 mM) Ethanol : 46 mg/mL (186.8 mM) |
| 生物活性 | |
| In vitro(体外研究) | Loxoprofen sodium(LOX) does not affect the proliferation and viability of LLC cells in vitro. HUVECs treated with LOX results in the inhibition of the tubular formation. Treatment with 50 mg/ml LOX reveals a 33% decline in in vitro angiogenesis, compared with vehicle-treated HUVECs. This inhibition is presumably due to inhibition of VEGF activity. |
| In vivo(体内研究) | Loxoprofen sodium (LOX), inhibits in vivo growth of implanted Lewis lung carcinoma (LLC). Intratumoral vessel density in LOX-treated mice is significantly lower than that of mice without treatment. Intratumoral expressions of vascular endothelial growth factor (VEGF) mRNA are attenuated by the LOX treatment. LOX suppresses both intratumoral and systemic VEGF protein in LLC-implanted mice. LOX alsoinhibits tubular formation of primary cultured human umbilical vein endothelial cells, presumably due to the inhibition of VEGF. In patients with advanced non-small cell lung cancer, LOX medication (120 mg/day) for a week significantly decreases the plasma VEGF level. |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | Immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：